Effect of Evolocumab on Vascular Function
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT03626831
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Registry
-
NCT03626831
-
- Other papers using this trial's data
- Endothelial function in high-risk patients with ezetimibe therapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT03626831. Randomized; triple masking; primary purpose treatment. Start 2019-04-04 (actual); primary completion 2021-04-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Evolocumab on Vascular Function
- Acronym
- EVO
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Evolocumab Prefilled Syringe
- Intervention (Drug)
- Placebos
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
Record details
- Record id
cardio:ct-nct03626831- Content hash
f040e645112af5c44ed221058611a94c37639299c1a008666e88dfb2da640c36